The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial offering period The subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025   MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V.

Major stock indexes pulled back as the final trading month of the year began, with shares of big tech and cryptocurrency-tied firms falling amid risk-off sentiment.

Guru Stock PicksRoyce International Premier Fund has made the following transactions:Reduce in XTER: EVD by 0.78%Sold out in ASX:JLGAdd in XPAR: PLNW by 62.41%New

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.

Memo also reportedly mentions vaccines for flu and pneumonia.

The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”) at the extraordinary general meeting (“EGM”) held by CureVac on November 25, 2025. At the EGM, over 99.16% of votes cast by CureVac shareholders were in favor of the proposals relating to the Offer. BioNTech expects to complete the pending Offer as soon as reasonably practicable.

BioNTech SE ( BNTX ) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ilhan Celik Michael Wenger Ramón Zapata-Gomez - CFO & Member of Management Board Douglas Maffei - Vice President of Strategy & Investor Relations Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Jay Lee - Morningstar Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Terence Flynn - Morgan Stanley, Research Division William Maughan - Clear Street LLC., Research Division Jae-Young Park Malcolm Hoffman - BMO Capital Markets Equity Research Asthika Goonewardene - Truist Securities, Inc., Research Division William Zhang Presentation Unknown Executive [Audio Gap] by Annemarie Hanekamp, our Chief Commercial Officer.

Allianz SE grew its position in BioNTech SE Sponsored ADR (NASDAQ: BNTX) by 635.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 5,880 shares of the company's stock after acquiring an additional 5,080 shares during the period. Allianz SE's holdings in BioNTech were worth $626,000

Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly COVID-19 pandemic.